Both liarozole groups presented a higher number of AEs than the placebo group; however, the difference between groups was not significant (liarozole 75 or 150 mg vs. placebo, P ≥ 0·062), and AE incidence did not appear to be related to liarozole dose.
Improvement in DLQI score was observed in both liarozole groups.
Liarozole induced a modest, significant, dose-related decrease in the bone formation marker serum PINP from baseline in both liarozole groups (75 mg: −11·72%, P = 0·0224; 150 mg: −16·00%, P = 0·0036); this decrease was transient and returned to baseline concentrations 4 weeks after termination of liarozole treatment.
Mean IGA and scaling scores decreased from baseline in both liarozole groups at weeks 8 and 12 vs. placebo; erythema and pruritus scores were similar between treatment groups.
During the treatment period, mean DLQI score remained stable in the placebo group, whereas an improvement in mean DLQI score was observed in both liarozole groups, followed by worsening during the follow-up period.
Both groups, however, had endorsed DeVore, not Fiorina.
Both groups, however, proclaim loyalty to a fundamentalist interpretation of Islam.
Both groups, however, had significantly lower I.Q.'s than a comparison group of children raised by their biological families.
Both groups, however, share some risk factors.
Representatives of both groups, however, denied that their members were behind the violence.
